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The objective of the present study is to formulate and characterize a nanoparticulate-based formulation of a macromolecule in
a hydrophobic ion pairing (HIP) complex form. So far, HIP complexation approach has been studied only for proteins with
molecular weight of 10–20kDa. Hence, we have selected bovine serum albumin (BSA) having higher molecular weight (66.3kDa)
asamodel protein anddextran sulphate (DS) asacomplexing polymer to generate HIP complex. Wehave prepared andoptimized
the HIP complex formation process of BSA with DS. Ionic interactions between basic amino acids of BSA with sulphate groups
of DS were conﬁrmed by FTIR analysis. Further, nanoparticles were prepared and characterized with respect to size and surface
morphology. We observed signiﬁcant entrapment of BSA in nanoparticles prepared with minimal amounts of PLGA polymer.
Finally, results of circular dichroism and intrinsic ﬂuorescence assay have clearly indicated that HIP complexation and method of
nanoparticle preparation did not alter the secondary and tertiary structures of BSA.
1.Introduction
Protein-based therapeuticssuch as antibodies, blood derived
products, and vaccines have been widely investigated in the
past decade to treat a variety of disorders [1]. Development
of a nanoparticulate-based dosage form of these molecules
is still considered as a major challenge by scientists in
the drug delivery ﬁeld. Single emulsion (O/W), double
emulsion(W/O/W),andemulsionpolymerizationhavebeen
widely employed to prepare nanoparticles. Except emulsion
polymerization, the other two methods (single and double
emulsion) employ organic solvents and sonication during
nanoparticle preparation. Protein-based therapeutics tend to
exhibit rapid denaturation and conformational change due
to sonication and exposure to organic solvents [2, 3]. These
molecules may aggregate and eventually lose their biological
activity due to physical and chemical stress observed during
formulation development, for example, exposure to organic
solvents and sonication. These molecules may also denature
orlose theirbiologicalactivity during storage and lyophiliza-
tion [4–6]. Sonication is employed to ensure homogeneous
dispersion of an emulsion. However, sonication may result
in large pressure and temperature gradient which may cause
denaturation and aggregation of the protein molecule [7].
Moreover, sonication also causes generation of high shear
force and free radicals which cause protein denaturation [7].
Organic solvents preferentially interact with nonpolar amino
acids of protein via hydrophobic interactions. Normally,
these nonpolar amino acids are present in the core of the
protein structure. As a result, in presence of organic solvents,
the native structure and conformation of the protein can be
altered. This process may result in loss of biological activity
of a protein molecule. Another crucial formulation-related
limitation of protein molecules is their hydrophilicity. Due
to their hydrophilic nature, these molecules often partition
poorly into the polymeric matrix during encapsulation
resulting in minimal loading in nanoparticles [1]. Due
to poor loading of these molecules, a higher amount of
polymer is needed to develop a formulation. Poly lactic-co-
glycolic acid (PLGA) is one of the most widely employed
biocompatible and biodegradable polymers utilized in the
preparation of nanoparticles. However, higher amounts of
PLGA can lower the stability of protein molecules as protein
moleculeswerefoundtobeunstableinpresenceoflacticacid2 Journal of Drug Delivery
and glycolic acid which are degradation products of PLGA
[6, 8, 9].
Hydrophobic ion pairing (HIP) complexation based
approach has gained wide acceptance in the delivery of
peptide and protein based therapeutics [10–14]. In this
approach, ionizable functional groups of a drug molecule
are ionically complexed with a surfactant or polymer with
oppositely charged functional groups. The resulting drug-
polymer or drug-surfactant complex is known as HIP
complex. Since the hydrophilic protein molecule exists in a
complex form which is relatively hydrophobic, its partition
into the polymeric matrix can be signiﬁcantly enhanced
during encapsulation [10, 15]. Protein and polymer (used
for HIP complexation) primarily interact due to ionic
interactions resulting in the formation of a HIP complex.
Thecomplexcandissociate inpresenceofoppositelycharged
ions. Further, HIP complexation would obviate the use
of any covalent modiﬁcation in proteins to impart these
moleculesmorehydrophobicity.Covalentmodiﬁcationsmay
also result in irreversible loss in the biological activity of
these molecules. Various studies have been performed in
the past to understand the nature of protein-surfactant
interactions. HIP complexation approach has been studied
with various peptide and protein based therapeutics such
as leuprolide, insulin, melittin, lysozyme, and so forth [10–
13]. HIP complexation of protein-based therapeutics has
been attempted to overcome various barriers associated with
delivery of protein molecules such as bioavailability and
stability [13, 16]. Moreover, HIP complexation can also
impart conformational stabilitytotheproteinmolecule[13].
HIP complexation of large protein molecules is challeng-
ing primarily due to following reasons. Large molecules usu-
ally contain many groups with opposite charges which may
hinder the complexation process. So far, basic amino acids
have been employed (mainly lysines and arginines) to form a
HIP complexwith anionic surfactant molecules. However, in
large protein, aspartic acid and glutamic acid are also present
on the surface in signiﬁcant numbers which would repel the
negatively charged complexing molecules. Second, in a large
molecule, charge density plays a very crucial role. There is
usually more surface area per charge in a large protein than
for a small protein molecule. Hence, selection of a surfactant
or polymer with an appropriate chain length is necessary
to form the HIP complex. Activity of a protein molecule
also depends on its secondary and tertiary structures. These
structures are stabilized by various noncovalent interactions
such as electrostatic interactions, hydrogen bonds, Van der
walls forces, and hydrophobic interactions [17–19]. Hence,
a complexing agent which would not perturb the secondary
and tertiary structure of the protein must be selected. So far,
various surfactant molecules have been selected to prepare
HIP complex. In the present study, we have investigated
HIP complex formation by employing dextran sulphate, a
polysaccharide-based molecule.
Bovine serum albumin (BSA) is a 66.3kDa molecule. It
is globular in shape and has been widely used as a model
protein[20,21].Dextransulphate,(DS,molecularweight:9–
20kDa), a polysaccharide-based polymer, has been selected
forcomplexation.Inthispaper,HIPcomplexofBSAwithDS
has been described. Solid in oil in water (S/O/W) emulsion
method has been employed to prepare nanoparticles. After
preparation, nanoparticles have been characterized with
respect to particle size and surface morphology. Finally, the
eﬀect of HIP complexation and nanoparticle preparation
on the secondary and tertiary structure of BSA has been
studied by circular dichroism and intrinsic ﬂuorescence
assay, respectively.
2.Materialsand Method
Materials: Bovine serum albumin, dextran sulfate sodium
salt (molecular weight 9000–20000da), Poly (DL-lactide-
co-glycolide) (PLGA 85:15, molecular weight of 50,000–
75,000da), bicinchoninic acid (BCA), and copper sulphate
wereprocuredfromSigmaAldrich.Micro-BCAproteinassay
kit was purchased from Thermo scientiﬁc. All the solvents
and other reagents of analytical grade were purchased
from local suppliers and used as received without any
further puriﬁcation. Doubledistilled water (DDW) was used
throughout the entire study.
2.1. Preparation of HIP Complex of BSA and DS. Stock
solutions of BSA and DS were prepared in citrate buﬀer
pH 4.4 and DDW, respectively. BSA consists of various
basic amino acids (60 lysine and 26 arginine residues) while
DS contains 2.3 sulphate groups per glucosyl residue. HIP
complex was formed spontaneously as both the aqueous
solutions were mixed.
2.2. Eﬀect of Diﬀerent Molar Ratios of DS to BSA on HIP
Complex Formation. Stock solutions of BSA and DS were
prepared as mentioned earlier. HIP complexeswere prepared
in diﬀer en tm ola rra tiosofDS/BSA.T h em ola rra tioss tudied
were 0.29, 0.58, 0.87, and 1.15. These molar ratios represent
the addition of diﬀerent amounts of DS into previously
prepared BSA solution (5mg/mL in pH 4.4 citrate buﬀer).
Once formed, HIP complex was vigorously vortexed for 3
minutes followed by centrifugation at 10000RPM for 10
minutes to separate the supernatant. Uncomplexed BSA was
measured in the supernatant using BCA assay. Percentage of
complexed BSA was calculated according to the following
equation:
%C o m p l e x e dB S A
=
InitialamountofBSA−amountofBSAinsupernatant
Initial amount of BSA

∗ 100.
(1)
2.3. Dissociation of BSA from HIP Complex. Dissociation
of BSA from HIP complex was studied to characterize the
nature of interaction between BSA and DS. Freeze dried
complex containing 5mg of BSA was accurately weighed
and incubated in presence of DI water and aqueous solution
containing 10mM Na2HPO4. These solutions were vortexed
andkeptforequilibriumfor3hrsatroomtemperature.AfterJournal of Drug Delivery 3
3hrs, these solutions were subjected to centrifugation and
supernatant was collected. The concentration of dissociated
protein in the supernatant was then measured with BCA
assay.
2.4.FTIRStudy. FTIRanalysis ofBSA,DS,andHIPcomplex
was carried out with an infrared spectrophotometer (Perkin-
Elmer, Waltman, MA). The samples were brought into
intimate contact with the diamond crystal by applying a
loading pressure. Samples were casted on diamond crystal
top-plate of Attenuated Total Reﬂectance (ATR) accessory
and scanned between 650–1800cm−1.S p e c t r ao b t a i n e d
using this device represents the average of 32 individual scan
possessing a spectral resolution of 4cm−1.
2.5. Preparation of Nanoparticles. PLGA 85:15 was used
as a polymer to prepare nanoparticles. Nanoparticles were
prepared by using solid in oil in water (S/O/W) emul-
sion method published earlier with minor modiﬁcations
[15]. Brieﬂy, 5mg of BSA in complex form was used for
preparation of nanoparticles. PLGA 85:15 was dissolved
in methylene chloride. Two diﬀerent ratios of BSA: PLGA
85:15 (1:5 and 1:10) were employed to prepare the
nanoparticles. PLGA solution was gradually added to the
earlier prepared HIP complex. Total volumes of methylene
chloride and vortexing time were optimized to obtain S/O
dispersion.About4-5mLofmethylenechloridewasrequired
to completely disperse the HIP complex. Sonication was
performed for about ≈3 minutes using tip sonicator (Fisher
100 Sonic dismembrator, Fisher Scientiﬁc) at power output
of 25–30W to obtain the ﬁne S/O dispersion. To this S/O
dispersion, external aqueous phase (30mL, 1% PVA) was
added followed by further sonication for ≈3-4 minutes. This
procedure resulted in S/O/W nanoemulsion which was kept
on a shaker bath at room temperature for 15–20 minutes
followed by complete evaporation of methylene chloride
using a Rotavap. Following evaporation, the nanodispersion
was centrifuged for 50 minutes at 22,000g. Nanoparticles
were washed two times with DI water to remove any surface
bound BSA and PVA. Similarly, blank nanoparticles were
also prepared by employing only polymer (PLGA 85:15) in
similar amounts.
2.6. Characterization of Nanoparticles
2.6.1. Entrapment Eﬃciency of Nanoparticles. Entrapment
eﬃciency was measured according to an earlier published
protocol [20, 21] with minor modiﬁcations. Brieﬂy, 1mL of
nanosuspension was added to 9mL of methylene chloride
solution which was then vortexed for 10–15 minutes to
dissolve the polymer completely. Later, this solution was
subjected to centrifugation which resulted in formation of
a protein pellet. Methylene chloride was carefully separated
and the pellet was dissolved in 10mL of PBS buﬀer.
Concentration of BSA in the aqueous phase was measured
using Micro-BCA assay. Absorbance from the samples
were corrected by subtracting the absorbance from blank
nanoparticles prepared using PLGA 85:15.
2.6.2. Particle Size Measurement. Previously published pro-
tocol [15] was followed to measure the mean particle size
and polydispersity of nanoparticles using a DLS instrument
(Brookhaven Inst. Co., USA). Particle size analysis was
carried out at an operating angle of 90◦Ca n dt e m p e r a t u r e
of 25◦C. A dilute sample of the nanosuspension was taken
for particle size analysis, and at least three measurements of
each batch were carried out.
2.7. SEM and TEM Analysis. For SEM analysis, freeze dried
specimen was applied on a sticky carbon ﬁlm positioned
on an aluminum stub. Specimens were sputter coated with
gold-palladium and observed with the ﬁeld-emission SEM
XL30 (FEI, Hillsboro, OR). For TEM study, a drop of
nanosuspension was deposited on TEM cooper grid with
carbon ﬁlm. After drying, it was observed under Phillips
TEM CM12 (FEI, Hillsboro, OR).
2.8. Evaluation of Secondary Structure of BSA after Disso-
ciation from HIP Complex and Release from Nanoparticles
with Circular Dichroism. HIP complex was dissociated in
presence of 1mL of 10mM Na2HPO4 solution, and free
BSA was quantiﬁed using BCA assay. Previously prepared
PLGA nanoparticles were incubated in presence of 1mL of
10mM Na2HPO4 solution and kept overnight. BSA released
from the nanoparticle formulation was quantiﬁed on the
following day with BCA assay. Finally, standard solution of
BSA was prepared in 10mM Na2HPO4 solution and used as
a control. Final concentrationof each sample was adjusted to
0.05mg/mL. Circular dichroism (CD) spectra were collected
using Jasco 720 spectropolarimeter at room temperature.
The spectra of all the samples were collected over a range
of 200–250nm with a cuvette of 1cm path length at a scan
speed of 20nm/min. Data was further processed for blank
subtraction and noise reduction and an average of three
signals was recorded. All CD measurements are reported as
ellipticities (θ,m d e g ) .
2.9. Evaluation of Tertiary Structure of BSA after Dissoci-
ation from HIP Complex and Release from Nanoparticles
with Intrinsic Fluorescence Assay. Fluorescent measurements
were carried out at room temperature with ﬂuorescence
spectrophotometer (Photon Technology International). The
procedure to recover BSA after dissociation of HIP com-
plex and from nanoparticles has been mentioned previ-
ously. Standard and test samples were prepared in 10mM
Na2HPO4 solution (ﬁnal BSA concentration was adjusted to
0.1mg/mL). We compared ﬂuorescence spectra of standard
with BSA obtained after dissociation from HIP complex and
BSA released from nanoparticles. All samples were excited
at a wavelength of λex 295nm, and emission spectra were
collected between 310–400nm. λex 295nm was chosen to
selectively excite tryptophan amino acid of BSA. Quartz cells
(12.5L × 12.5mmW) having 3mL of sample capacity were
used for measurement. Fluorescent emission spectra were
recorded and are displayed in terms of relative ﬂuorescence.4 Journal of Drug Delivery
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Figure 1: Eﬀect of molar ratio of DS:BSA on HIP complex
formation.
3.Resultand Discussion
Proteins and peptides represent a rapidly growing class
of therapeutic drugs with more than 200 biopharmaceu-
ticals in the market and many more at diﬀerent stages of
development.Design ofnanoparticle-based formulationsfor
protein-based therapeutics has become a major challenge
for drug delivery scientists because of poor encapsulation
in polymeric matrix and rapid denaturation in presence of
organic solvents and sonication [2, 3]. HIP complexation
based approach can be explored to deliver peptide and
protein-based therapeutics. It can overcome various stability
related issues, enhance drug loading in nanocarriers and
improve drug permeation across biological membrane [10–
14, 22]. So far, HIP complex based approach has been only
studied with small peptide and protein-based therapeutics.
Hence, BSA was selected as a model protein in the present
study because of its higher molecular weight (66.3kDa) and
well-known secondary and tertiary structure.
Isoelectric point (pI) of BSA is ≈4.5, and the protein
consists of various basic amino acids (60 lysine and 26
arginine residues). Hence, we have slightly altered the pH of
BSAsolutionandpreparedstocksolutionofBSAatpH4.4in
citrate buﬀer. Being hydrophilic in nature, these amino acids
are mostly found on the protein surface. Amino groups of
these basic amino acids are protonated based on the pH of
surrounding medium. At this pH, HIP complex was formed
immediately upon mixing of aqueous solutions of BSA and
DS. This data conﬁrms the importance of pH of the protein
solutionpriortoHIPcomplexation.Ingeneral,itiscrucialto
understand the eﬀect of pH on stability of protein molecule.
One should also consider the possibility of other stability
related issues which may arise by changing the pH of protein
solution prior HIP complexation.
The eﬀect of molar ratios of DS/BSA on HIP complex
formation has been studied. We calculated the molar ratios
based on the total number of lysine amino acids present on
the surface of BSA (60 lysine amino acid). HIP complexes
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Figure 2: Comparative dissociation of BSA from HIP complex in
t h ep r e s e n c eo fD Iw a t e ra n d1 0m MN a 2HPO4 solution.
were prepared using the following molar ratios of DS/BSA
(0.29, 0.58, 0.87, and 1.15). Theoretically, these molar ratios
represent the amounts of DS added which was suﬃcient
to complex with 15, 30, 45, and 60 basic amino acids of
BSA. Figure 1 shows the complexation of BSA with DS at
diﬀerent molar ratios. An excellent correlation is observed
between increments in the molar ratio of DS/BSA with the
amount of BSA complexed with DS (Figure 1). In fact at a
molar ratio of 1.15, more than 90% of BSA molecules were
ionically complexed with DS. This data clearly indicates the
involvement of basic amino acids in the formation of HIP
complex.
We also hypothesized ionic interactions as a driving force
for complexation of BSA with DS. In order to conﬁrm our
hypothesis, we performed dissociation studies of the HIP
complex in presence of oppositely charged ions (HPO
−2
4 ).
Results of this experiment are shown in Figure 2.W h e nH I P
complex was incubated in DI water, no dissociation of BSA
from HIP complex was observed. This could be due to low
ionic strength of DI water. However, the presence of 1mL of
10mM Na2HPO4 solution caused complete dissociation of
the HIP complex and the solution became clear. These data
further conﬁrm the presence of ionic interactions between
amino groupofbasicamino acids inBSAandsulphategroup
of DS. Dissociation of HIP complex in presence of counter
ions has also been reported by other investigators [13, 15].
FTIR study was performed to understand the nature of
interactions between amino group of basic amino acids in
BSA and sulphate group of DS. FTIR analysis was performed
by other investigators to characterize ionic interactions
between oppositely charged functional groups [12, 23, 24].
Due to overlapping shift in a FTIR spectrum, we did
not follow peak shift associated with the protein. Instead,
the interaction of sulphate group of DS was studied in
the IR region. Following are the characteristic peaks of
sulphate group of DS in the IR region: (a) 802cm−1:S -
O-S vibration, (b) 1017cm−1: symmetric SOO−stretching
vibration, and (c) 1225cm−1: asymmetric SOO−stretching
vibration. Appearance of these peaks in the IR spectra is
close to previously published results [23–25]. Due to ionicJournal of Drug Delivery 5
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Figure 3: FTIR spectra of (a) BSA, (b), DS and (c) HIP complex.
Table 1: Particle size, polydispersity, and entrapment eﬃciency of
diﬀerent batches of nanoparticles. Values are given as means ± SD
(n = 3).
Ratio of BSA to
PLGA 85:15
Particle size
(nm) Polydispersity %E n t r a p m e n t
eﬃciency
1:5 193.4 ±3.1nm 0.011 67.8 ±8.6
1:10 201.6 ±2.2nm 0.010 79.7 ±4.1
interaction between amino and sulphate groups in HIP
complex, the peak intensity of the sulphate group in the
IR region may be attenuated signiﬁcantly. Results of this
study are shown in Figure 3. These results clearly indicate a
signiﬁcantreductioninthepeakintensitiesofsulphategroup
in the IR region which again conﬁrmed the presence of ionic
interactions between amino and sulphate groups in the HIP
complex.
We prepared nanoparticles of the complex using S/O/W
emulsion method. This method of preparation oﬀers signiﬁ-
cant advantages over conventional methods of nanoparticles
preparation such as single and double emulsion method.
In the conventional methods of preparation, protein is
initially dissolved in an aqueous phase and later emulsiﬁed
in the presence of an organic phase using sonication. Most
proteindenaturationoccursduringthis stageofnanoparticle
preparation due to water-organic phase interface. Excessive
stress during sonication process and generation of free
radicals can cause protein unfolding and denaturation. In
S/O/W emulsion method, protein-polysaccharide powder
was employed in the preparation of nanoparticles instead
of protein in solution form. Further, in the powder form,
kinetic mobility of the protein is restricted compared to
solution form [20, 21]. Moreover, complexation with DS
would not only restrict conformational ﬂexibility of BSA but
would also impart additional steric shielding to the protein
molecule. We optimized the total volume of organic solvent
needed and the sonication time to prepare nanoparticles.
Nanoparticleswere alsocharacterized withrespect toparticle
size (Table 1) which range between 150–200nm. SEM and
TEM studies were performed to study the surface morphol-
ogy. Results of these studies are shown in Figures 4 and
Acc. V Spot Magn
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Figure 4: SEM images of nanoparticles.
1µm
Figure 5: TEM images of nanoparticles.
5, respectively. These results conﬁrmed that particles have
smooth surface and spherical shape.
O n eo ft h ei m p o r t a n tg o a lo ft h ep r e s e n ts t u d yw a st o
achieve higher encapsulation of BSA in nanoparticles by
employing minimal amounts of polymer (PLGA 85:15).
Nanoparticles were prepared by employing two diﬀerent
ratios of protein: PLGA (1:5 and 1:10). BSA entrapment
in nanoparticles was more than 65% in both cases (Table 1).
This data clearly shows a signiﬁcant entrapment of BSA in
PLGA matrix. As the amount of PLGA was increased to
prepare nanoparticles, entrapment of BSA in nanoparticles
was enhanced as well. This could be attributed to enhanced
hydrophobicinteractions of BSAin HIP complex with PLGA
polymer. Due to these hydrophobic interactions, partition
of BSA (in HIP complex form) in the polymeric matrix of
PLGA was also signiﬁcantly enhanced.
The eﬀect of HIP complexation and nanoparticle prepa-
ration on secondary structure of BSA was evaluated by
CD spectra. Weak physical interactions such as electrostatic
interactions, hydrogen bonds, Van-der-waals forces, and
hydrophobic interactions stabilize secondary structure of
the protein. During HIP complex formation, DS interacts
extensively with BSA which involves abovementioned forces.
So, it is quite possible that DS has altered the native
conformation of BSA. Similarly, during nanoparticle prepa-
ration, powder form of BSA-DS complex was sonicated in6 Journal of Drug Delivery
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Figure 6: CD spectra of standard solution of BSA, BSA recovered
after dissociation from HIP complex and BSA after release from
diﬀerent batches of nanoparticles.
presence of organic solvents. These processes could possibly
denature BSA. CD analysis was performed to understand the
impact of these formulation factors on secondary structure
of BSA. Freshly prepared BSA in 10mM Na2HPO4solution
was selected as control. Figure 6 depicts the CD spectra
of standard BSA solution, BSA obtained from dissociation
of HIP complex, and BSA released from both batches of
nanoparticles. Results clearly show a signiﬁcant overlap
in peak shape throughout the region studied. This data
also conﬁrms that the secondary structure of BSA was
not perturbed due to HIP complexation or treatment with
organic solvent and sonication. Enhanced stability of BSA
towards organic solvents and sonication may be explained
by the following reasons. First, HIP complexation might
have provided conformation stability and steric shielding
to the BSA molecule. Moreover, with S/O/W emulsion
method, the probability of protein denaturation has been
signiﬁcantly minimized compared to conventional method
such as W/O/W emulsion method. In S/O/W emulsion
method, proteinmoleculesare encapsulated in thesolid state
relative to W/O/W emulsion method where solution form
of protein is employed. In the solid state, the detrimental
eﬀect of sonication at water-organic phase interface is also
minimal.
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Figure 7: Intrinsic ﬂuorescence assay of standard solution of BSA,
BSA recovered after dissociation from HIP complex and BSA after
release from diﬀerent batches of nanoparticles.
We compared the intrinsic ﬂuorescence spectra of freshly
prepared BSA with BSA obtained after dissociation from
HIP complex and BSA released from diﬀerent batches of
nanoparticles. BSA contains a buried tryptophan amino
acid in its hydrophobic core. Fluorescence of tryptophan is
extremely sensitive to polarity of its surrounding medium
[26]. Changes in the ﬂuorescence intensity, wavelength of
maximum ﬂuorescence emission, and quantum yield are
accepted parameters to study tertiary structure of protein.
Results of this study are shown in Figure 7.I ti sv e r yc l e a r
from this data that intensity and wavelength of maximum
ﬂuorescence(335nm)aresimilarinallthesamples.Thisdata
conﬁrmed thattertiary structureofBSAwasnotsigniﬁcantly
altered following dissociation from HIP complex and also
afterrelease from nanoparticles. This resultalso corroborates
with ourpreviousCDspectra resultswhere wehaveobserved
no signiﬁcant change in secondary structure of BSA due to
HIP complexation and nanoparticle preparation.
4.Conclusions
This study for the ﬁrst time shows the feasibility of forming
HIP complex of a large protein such as BSA with dextran
sulphate as a complexing polymer. This study conﬁrms
the involvement of basic amino acids in the formation of
HIP complexation. Dissociation studies of HIP complex in
presence of oppositely charged ions (HPO
−2
4 )a sw e l la sF T I R
studies have revealed presence of ionic interactions between
basic amino acids in BSA and sulphate groups of DS. We
successfully preparedand characterized nanoparticlesofBSA
in HIP complex form using S/O/W emulsion method. SEM
and TEM studies revealed smooth surface and sphericalJournal of Drug Delivery 7
shape of nanoparticles. Signiﬁcant entrapment of BSA in
nanoparticles was obtained when low amounts of PLGA
85:15 was employed. Finally, CD analysis and intrinsic ﬂuo-
rescence data revealed that secondary and tertiary structures
of BSA were not aﬀected due to HIP complexation and
nanoparticle preparation. HIP complexation approach can
be employed to enhance loading of large proteins including
antibody-based therapeutic molecules in colloidal dosage
forms.
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